Prokidney PROK
NASDAQ PROK
$1.72 +0.01 (+0.58%)
At close: Oct 2, 2026 · 4:00 PM EDT

Prokidney (PROK) Return on Equity [ROE] (2022)

Updated

Prokidney (PROK) recorded Return on Equity [ROE] of -901.95% in Q2 2022, down 484.41 percentage points from the prior quarter.

Analysis

Prokidney (PROK) Return on Equity [ROE] (2022) Analysis & Trends

For FY2021, Prokidney reported Return on Equity [ROE] of -299.86%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Prokidney 879.33 Mn 1.99 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -901.95%
Mar 31, 2022 -417.54%
API Access

Prokidney Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=PROK&period=max&api_key=YOUR_API_KEY